Company Overview of Anacor Pharmaceuticals, Inc.
Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. The company’s lead product candidate is crisaborole topical ointment, 2%, anti-inflammatory phosphodiesterase-4 inhibitor, which is in Phase III clinical trials for the treatment of mild-to-moderate atopic dermatitis and psoriasis. It is also developing AN3365, an antibiotic product candidate for the treatment of infections caused by Gram-negative bacteria. The company has collaboration agreements with t...
1020 East Meadow Circle
Palo Alto, CA 94303
Founded in 2000
Key Executives for Anacor Pharmaceuticals, Inc.
Chief Financial Officer and Executive Vice President
Executive Vice President, General Counsel and Secretary
Chief Medical Officer and Senior Vice President of Clinical Development
Chief Commercial Officer and Executive Vice President
Vice President, Secretary and Director
Compensation as of Fiscal Year 2016.
Anacor Pharmaceuticals, Inc. Key Developments
Anacor Pharmaceuticals Files Form 15
Jul 5 16
Anacor Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock, par value $0.001 per share under the Securities Exchange Act of 1934, as amended.
Anacor Pharmaceuticals, Inc.(NasdaqGM:ANAC) dropped from NASDAQ Biotechnology Index
Jul 4 16
Anacor Pharmaceuticals, Inc. has been removed from NASDAQ Biotech Index.
Anacor Pharmaceuticals, Inc.(NasdaqGM:ANAC) dropped from NASDAQ Composite Index
Jun 26 16
Anacor Pharmaceuticals, Inc. has been removed from Nasdaq Composite Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 16, 2016
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries